3-Methyladenine can depress drug efflux transporters via blocking the PI3K-AKT-mTOR pathway thus sensitizing MDR cancer to chemotherapy

Journal of Drug Targeting

Volumn 22, Issue 9, 2014, Pages 839-848

  Zou, Zhenyou ^a,b   Zhang, Jing ^c   Zhang, Haiyang ^c   Liu, Huan ^c   Li, Zhiguo ^b   Cheng, Dan ^d   Chen, Jun ^d   Liu, Lu ^a   Ni, Mengjie ^a   Zhang, Yu ^a   Yao, Jun ^a   Zhou, Jun ^a   Fu, Junjie ^e   Liang, Yong ^a  

^a TAIZHOU UNIVERSITY   (China)

^b PURDUE UNIVERSITY   (United States)

^c NANJING UNIVERSITY   (China)

^d NANJING AGRICULTURAL UNIVERSITY   (China)

^e ZHEJIANG UNIVERSITY   (China)

Author keywords

3 Methyladenine; Drug efflux transporters; Multi drug resistance; PI3K AKT mTOR pathway

Indexed keywords

3 METHYLADENINE; BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEINS AND BINDING PROTEINS; DOXORUBICIN; FLUORESCEIN ISOTHIOCYANATE; MAMMALIAN TARGET OF RAPAMYCIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PREGNANE X RECEPTOR; PROTEIN KINASE B; 3-METHYLADENINE; ABC TRANSPORTER; ADENINE; ANTINEOPLASTIC AGENT; MTOR PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CONTROLLED STUDY; DRUG ACCUMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; DRUG EFFECTS; DRUG RESISTANCE; HUMAN; TUMOR CELL LINE;

ADENINE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MICE; MICE, INBRED BALB C; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEINS; PACLITAXEL; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; TOR SERINE-THREONINE KINASES;

EID: 84911460734     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2014.936870     Document Type: Article

References (32)

1. American Cancer Society, Inc. Cancer facts and figures. American Cancer Society 2012;500812:1-8.
2. Wang J, Pursell NW, Samson ME, et al. Potential advantages of CUDC-101, a multi-targeted HDAC, EGFR, and HER2 inhibitor, in treating, drug resistance and preventing cancer cell migration and invasion. Mol Cancer Ther 2013;12:925-36.
3. Nature America Inc. Cancer multidrug resistance: progress in understanding the molecular basis of drug resistance in cancer promises more effective treatments. Nat Biotechnol 2000; 18(Suppl):IT18-20.
4. Che XF, Nakajima Y, Sumizawa T, et al. Reversal of P-glycoprotein mediated multidrug resistance by a newly synthesized 1,4-benzothiazipine derivative, JTV-519. Cancer Lett 2002;187: 111-19.
5. Morschhauser J, Barker KS, Liu TT, et al. The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog 2007; 3:e164:1603-16.
6. Masayuki N, Akio E, Nobuyoshi N, et al. Clinical significance of multi-drug resistance associated protein and P-glycoprotein in patients with bladder cancer. J Urol 1997;157:1260-5.
7. Zou Z, Wu L, Ding H, et al. MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 1-mediated autophagy. J Biol Chem 2012;287:4148-56.
8. Gottesman MM, Fojo T, Bates SE. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615-27.
9. Michael D. The human ATP-binding cassette (ABC) transporter superfamily. National Library of Medicine (US). Bethesda (MD): NCBI; 2002.
10. Zhu H, Wu H, Liu X, et al. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol 2008;76:582-8.
11. Natalya SP, Mariya IM, Alya GV, et al. Silencing activity of 20-O-methyl modified anti-MDR1 siRNAs with mismatches in the central part of the duplexes. Fed Eur Biochem Soc 2011;85: 2352-6.
12. Florie B, Richard VL, Annemart K, et al. In vivo knock-down of multidrug resistance transporters ABCC1 and ABCC2 by AAV-delivered shRNAs and by artificial miRNAs. J RNAi Gene Silencing 2011;7:434-42.
13. Piet B, Raymond E, Marcel K, Jan W. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000;92:1295-1302.
14. Wu YT, Tan HL, Shui G, et al. Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class i and iii phosphoinositide 3-kinase. J Biol Chem 2010;285:10850-61.
15. Navaratnarajah P, Steele BL, Redinbo MR, Thompson NL. Rifampicin-independent interactions between the pregnane X receptor ligand binding domain and peptide fragments of coactivator and corepressor proteins. Biochemistry 2012:51:19-31.
16. Rodrigues AS, Dinis J, Gromicho M, et al. Genomics and cancer drug resistance. Curr Pharm Biotechnol 2012;13:651-73.
17. Takakuwa O, Oguri T, Ozasa H, et al. Over-expression of MDR1 in amrubicinol-resistant lung cancer cells. Cancer Chemother Pharmacol 2011;68:669-76.
18. Wang H, Chen XP, Qiu FZ. Overcoming multi-drug resistance by anti-MDR1 ribozyme. World J Gastroenterol 2003;9:1444-9.
19. Braga F, Ayres-Saraiva D, Gattass CR, Capella MAM. Oleanolic acid inhibits the activity of the multidrug resistance protein ABCC1 (MRP1) but not of the ABCB1 (P-glycoprotein): possible use in cancer chemotherapy. Cancer Lett 2007;248:147-52.
20. Shishido Y, Ueno S, Yamazaki R, et al. ABCG2 inhibitor YHO-13351 sensitizes cancer stem/initiating-like side population cells to irinotecan. Anticancer Res 2013;33:1379-86.
21. Peng H, Qi J, Dong Z, Zhang JT. Dynamic vs static ABCG2 inhibitors to sensitize drug resistant cancer cells. PLoS One 2010;5: 1-10.
22. Carpenter C, Auger K, Chanudhuri M, et al. Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the 85-kDa subunit. J Biol Chem 1993;268:9478-83.
23. Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Ann Rev Biochem 1998;67:481-507.
24. Vanhaesebroeck B, Waterfield MD. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 1999;253: 239-54.
25. Jimenez C, Hernandez C, Pimentel B. The p85 regulatory subunit controls sequential activation of phosphoinositide 3-kinase by Tyr kinases and Ras. J Biol Chem 2002;277:41556-62.
26. Philp AJ, Campbell IG, Leet C. The phosphatidylinositol 30-kinase p85{alpha} gene is an oncogene in human ovarian and colon tumors. Cancer Res 2001;61:7426-9.
27. Khaleghpour K, Li Y, Banville D. Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma. Carcinogenesis 2004;25:241-8.
28. Shao J, Evers BM, Sheng H. Roles of phosphatidylinositol 30-kinase and mammalian target of rapamycin/p70 ribosomal protein S6 kinase in K-Ras-mediated transformation of intestinal epithelial cells. Cancer Res 2004;64:229-35.
29. Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006;95:1148-54.
30. Urbano A, Gorgun G, Foss F. Mechanisms of apoptosis by the tyrphostin AG957 in hematopoietic cells. Biochem Pharmacol 2002;63:689-92.
31. Holmes D. PI3K pathway inhibitors approach junction. Nat Rev Drug Discov 2011;10:563-4.
32. Simon M, Arkadiusz O, Olga P, Poger LW. Finding a fitting shoes for cinderella: searching for a autophagy inhibitor. Autophagy 2010;6:805-7.